DRD
IOVA icon

Dennis R. Delaney’s Iovance Biotherapeutics IOVA Stock Holding History

Dennis R. Delaney’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$563K Hold
38,000
– – 0.18% 43
2026
Q2 		$158K Hold
38,000
– – 0.05% 58
2026
Q1 		$133K Hold
38,000
– – 0.05% 57
2025
Q4 		$104K Hold
38,000
– – 0.05% 48
2025
Q3 		$82.5K Hold
38,000
– – 0.04% 47
2025
Q2 		$65.4K Buy
+38,000
New +$94.6K 0.03% 48

Other funds holding IOVA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return

Dennis R. Delaney's IOVA Position: Q3 2026 in Review

Dennis R. Delaney held its Iovance Biotherapeutics (IOVA) position steady in Q3 2026 at 38,000 shares worth $563K. The position accounts for 0.18% of the portfolio, ranked #43.

Dennis R. Delaney first reported a position in IOVA in Q2 2025 and has held it in 6 quarters since. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Dennis R. Delaney held 38,000 shares of Iovance Biotherapeutics worth $563K as of Q3 2026.
  • Dennis R. Delaney left its Iovance Biotherapeutics share count unchanged in Q3 2026.
  • Iovance Biotherapeutics made up 0.18% of Dennis R. Delaney's portfolio in Q3 2026, its #43 holding.
  • Dennis R. Delaney first reported a position in Iovance Biotherapeutics in Q2 2025 and has held it in 6 quarters since.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Dennis R. Delaney's 13F filing for Q3 2026, filed 13 Nov 2026.